Part 3: Learning from the Industry: A Tefen Series: Operational Excellence in the Life Sciences

Overview:

Tefen Ltd conducted a study in 2008 & 2009 on 11 life sciences companies, including AstraZeneca, Bayer Schering, GSK Bio, Ipsen, Janssen, Merck Serono, Novartis, Nycomed, Schering Plough, and Wyeth. The research focused on their Operational Excellence (OpEx) programs and is discussed in this three part series. In part one of the study, “The State of the Industry,” Caldwell, Mathew, and O’Donnell discuss how the life sciences industry is being affected by the decline of blockbuster drugs, competition from generic manufacturers and the East, and the economic crisis. “Operational Excellence Programs in the Industry”, part two of this series, explored the benefits of a lean and six sigma approach, and the necessary management to make the program work. The conclusion of the series, “Learning from the Industry,” will explore lessons learned and best practices from the 11 companies researched for this article.

Author: Tefen

Find more white papers on Operational Excellence & Lean Six Sigma

View all white papers»